- Home
- GBIO vs DMAC Comparison
GBIO vs DMAC Comparison
Compare GBIO & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- DMAC
- Stock Information
- Founded
- GBIO 2016
- DMAC 2000
- Country
- GBIO United States
- DMAC United States
- Employees
- GBIO N/A
- DMAC N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- GBIO Health Care
- DMAC Health Care
- Exchange
- GBIO Nasdaq
- DMAC Nasdaq
- Market Cap
- GBIO 165.5M
- DMAC 172.7M
- IPO Year
- GBIO 2020
- DMAC N/A
- Fundamental
- Price
- GBIO $1.37
- DMAC $4.70
- Analyst Decision
- GBIO Strong Buy
- DMAC Strong Buy
- Analyst Count
- GBIO 2
- DMAC 3
- Target Price
- GBIO $7.50
- DMAC $7.00
- AVG Volume (30 Days)
- GBIO 179.9K
- DMAC 105.5K
- Earning Date
- GBIO 11-06-2024
- DMAC 11-13-2024
- Dividend Yield
- GBIO N/A
- DMAC N/A
- EPS Growth
- GBIO N/A
- DMAC N/A
- EPS
- GBIO N/A
- DMAC N/A
- Revenue
- GBIO $18,582,000.00
- DMAC N/A
- Revenue This Year
- GBIO $188.06
- DMAC N/A
- Revenue Next Year
- GBIO N/A
- DMAC N/A
- P/E Ratio
- GBIO N/A
- DMAC N/A
- Revenue Growth
- GBIO 514.08
- DMAC N/A
- 52 Week Low
- GBIO $1.10
- DMAC $2.14
- 52 Week High
- GBIO $4.65
- DMAC $4.95
- Technical
- Relative Strength Index (RSI)
- GBIO 26.45
- DMAC 63.73
- Support Level
- GBIO $1.24
- DMAC $3.96
- Resistance Level
- GBIO $2.57
- DMAC $4.21
- Average True Range (ATR)
- GBIO 0.21
- DMAC 0.21
- MACD
- GBIO -0.07
- DMAC 0.02
- Stochastic Oscillator
- GBIO 9.77
- DMAC 87.64
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.